1979 over 50% of the Upjohn R&D budget was being spent on the
prostaglandins. It was anticipated this class of molecules would
have many applications and be highly profitable. Sadly this did
not happen - the few prostaglandin products from this effort never
even repaid the money spent on developing them. Below is an
optimistic article from a 1979 American Pharmacy magazine.